Introduction Patients with type 2 diabetes mellitus (T2D) and established atherosclerotic cardiovascular disease (ASCVD) face a substantially elevated risk of major adverse cardiovascular events and premature mortality [1,2,3]
Contact: Brandyn Bissinger [email protected] Photos accompanying this announcement are available at
Smith filed a lawsuit in November of 2023, alleging: As a result of using Defendants Mounjaro, Plaintiff was caused to suffer from gastroparesis, which resulted in, among other things, development of Wernickes encephalopathy. While Eli Lilly has not responded directly in court to their case, it has noted in other filings that Mounjaro labels have always warned that it may be associated with "severe" gastrointestinal reactions
Less Common Reactions Some individuals may experience: Fatigue Injection site irritation Mild dizziness Anyone experiencing severe symptoms should seek medical attention immediately
So far, two pills have been approved for use by the U.S
By stimulating glucose-dependent insulin secretion and suppressing glucagon production, they are a cornerstone of the treatment of type 2 diabetes (DM2), particularly in patients with a higher risk of cardiovascular disease ( This narrative review describes the complex interplay between GLP-1 signalling and intestinal inflammation, highlighting both the potential benefits and limitations of GLP1 RAs in IBD management, with a particular focus on their promising role in selected obese IBD patients
